Treacherous finances for Multiple Sclerosis

I read an article in Neurology Today called New Supreme Court Case & the Complicated Accounting of MS Drugs which details some eye-opening realities about the cost of multiple sclerosis.  The article impetus was a Supreme Court agreement to hear Teva Pharmaceutical’s challenge to generic makers of its MS drug glatiramir acetate (Copaxone), a drug […]